<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D05A7DB0-DDE3-4B74-9054-DBA128A186AA"><gtr:id>D05A7DB0-DDE3-4B74-9054-DBA128A186AA</gtr:id><gtr:name>University Heart Centre Hamburg</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/56D224A7-85D8-4C83-9E88-1279DCF0FE07"><gtr:id>56D224A7-85D8-4C83-9E88-1279DCF0FE07</gtr:id><gtr:name>Welfare and Health Promotion</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:department>Medicine Dentistry and Biomedical Sci</gtr:department><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D05A7DB0-DDE3-4B74-9054-DBA128A186AA"><gtr:id>D05A7DB0-DDE3-4B74-9054-DBA128A186AA</gtr:id><gtr:name>University Heart Centre Hamburg</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/56D224A7-85D8-4C83-9E88-1279DCF0FE07"><gtr:id>56D224A7-85D8-4C83-9E88-1279DCF0FE07</gtr:id><gtr:name>Welfare and Health Promotion</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/1A802041-CC29-4710-84B9-E0923207F958"><gtr:id>1A802041-CC29-4710-84B9-E0923207F958</gtr:id><gtr:firstName>Kari</gtr:firstName><gtr:surname>Kuulasmaa</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A7D2F861-D1AC-4AEC-AE9B-AFA12D527424"><gtr:id>A7D2F861-D1AC-4AEC-AE9B-AFA12D527424</gtr:id><gtr:firstName>Hugh</gtr:firstName><gtr:surname>Tunstall-Pedoe</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/696CE1C8-E365-4765-9F3E-C105874C3B06"><gtr:id>696CE1C8-E365-4765-9F3E-C105874C3B06</gtr:id><gtr:firstName>Alun</gtr:firstName><gtr:surname>Evans</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/92A9E8CB-737D-45A2-B015-02E72E3158B2"><gtr:id>92A9E8CB-737D-45A2-B015-02E72E3158B2</gtr:id><gtr:firstName>Stefan</gtr:firstName><gtr:surname>Blankenberg</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C257AE0C-3294-494E-AE46-5B745D113033"><gtr:id>C257AE0C-3294-494E-AE46-5B745D113033</gtr:id><gtr:firstName>Frank</gtr:firstName><gtr:surname>Kee</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0601463"><gtr:id>3DCF2B36-2AF8-4951-B722-424C799E376B</gtr:id><gtr:title>Serum Biomarkers in the MORGAM Populations</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0601463</gtr:grantReference><gtr:abstractText>The role of risk factors, such as raised blood cholesterol and blood pressure to heart disease, to determining future heart disease and stroke has been known for more than thirty years. More recently the level of a protein (C reactive protein)in the blood has been shown to improve prediction but better prediction is needed to identify patients at increased risk, on whom preventive efforts can be concentrated. To do this it is necessary to follow up large groups of people to see if many novel new proteins (biomarkers) can improve our ability to identify persons at higher risk of developing heart disease or stroke. We need to study human populations as the reevance of studing these new factors in animals is dubious. MORGAM is a large European studt which has included 120,000 men and women in 9 countries. A sample of serum is available for all these persons and we will use the latest tecchnology to measure a battery of 19 Biomarkers, some of which are highly novel. The results obtained in the United Kingdom samples will be verified in other European poulations, in men and women separately. In this fashion we plan to derive a scoring system to quantify the cahace of developing a heart attack in the future so that steps can be taken to avert them. The Team is based at the Queen s University of Belfast and in Helsinki, Finland, and in Mainz, Germany.</gtr:abstractText><gtr:technicalSummary>Background: Cardiovascular disease is the leading cause of morbidity and mortality in the industrialised world. Biomarkers can substantially improve the early identification of high-risk patients for future cardiovascular events.
Aim of the Study: The primary aim is to produce a British/European risk score that allows improved risk prediction beyond that obtained from current scoring systems. The objective of the present proposal is to identify a single biomarker or a group of biomarkers which, in the primary prevention setting, are highly predictive of future cardiovascular disease. 
Methods: 
MORGAM (MOnica, Risk, Genetics, Archiving, and Monography, www.ktl.fi/morgam/) is a multinational study (53 cohorts in 9 countries) of the epidemiology and genetics of cardiovascular disease morbidity and mortality. These harmonized data are completely available at the MORGAM data centre. MORGAM is sufficiently large to permit the development of a biomarker instrument in the UK cohorts like Belfast (PRIME), Scotland (SHHS), Wales (Caerphilly), and London (UKWHS) which will then be compared to European populations with an overall sample size of 120,000 subjects. A panel of 21 easily detectable biomarkers covering distinct pathophysiological pathways has been selected. For the inflammatory pathways hs-CRP, PLA2 (PAF-AH), IL-18, sTNFR-1, hs-IL-10, and sICAM-1. To assess oxidative stress, MPO and PON will be determined. Hemodynamics and vascular remodelling are represented by (Nt-pro)BNP, (pro)ANP and TIMP-1, MMPs, and metabolic pathways include TSH, adiponectin, APO A-I and B 100. In additiion, renal function parameter will be assessed including cystatin C and neutrophil gelatinase associated lipocalin. The risk estimates will be derived primarily using time-to-event models. The predictive performance of the biomarkers will be evaluated in the UK training data-set and assessed in the overall European cohort.
Overall, the study concept provides unique opportunity to identify single biomarkers or a discrete panel of biomarkers of clinical relevance for early cardiovascular risk prediction in primary prevention.</gtr:technicalSummary><gtr:fund><gtr:end>2010-08-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>535734</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Heart Centre Hamburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Department of Cardiology, Electrophysiology</gtr:department><gtr:description>MORGAM project</gtr:description><gtr:id>CD54B801-E120-4DCB-B1C3-FD22345E7D50</gtr:id><gtr:impact>Publications in the development phase are entitled; 'Sensitive Troponin as long term predictor for cardiovascular and cardiac disease risk' along with a systematic review 'Is cardiac Tropinin a useful prognostic marker in healthy populations and those with stable coronary heart disease?' 'Vitamin D and risk of Cardiovascular disease in MORGAM' Based on this research we have been invited to publish a review paper entitled 'Clinical Utility of Multiple Biomarker Panels for Cardiovascular Disease Risk Prediction' accepted in Current Cardiovascular Risk Reports (Hughes, Kee and Salomaa).</gtr:impact><gtr:partnerContribution>The MORGAM Data Management Centre (MDC) is based at the National Institute of Health and Welfare. The MDC harmonizes the data from the various MORGAM participating centres and facilitates access to the database. The statistical analysis of the project is carried out here by MORGAM statisticians, datamanagers from this unit prepare datasets for analysis by other MORGAM collaborating Centres. Biomarker identification, selection and measurement is carried out at the Medical Clinic II laboratories at the Department of Cardiology in Mainz which moved to University Heart Centre, Hamburg, Germany in 2011.</gtr:partnerContribution><gtr:piContribution>The Principal Investigators have made a significant intellectual contribution to the project and faciliated access to the datasets.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Welfare and Health Promotion</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:department>Department of Chronic Disease Prevention</gtr:department><gtr:description>MORGAM project</gtr:description><gtr:id>627F3F7C-8047-4E42-A7FD-F5069F604AC9</gtr:id><gtr:impact>Publications in the development phase are entitled; 'Sensitive Troponin as long term predictor for cardiovascular and cardiac disease risk' along with a systematic review 'Is cardiac Tropinin a useful prognostic marker in healthy populations and those with stable coronary heart disease?' 'Vitamin D and risk of Cardiovascular disease in MORGAM' Based on this research we have been invited to publish a review paper entitled 'Clinical Utility of Multiple Biomarker Panels for Cardiovascular Disease Risk Prediction' accepted in Current Cardiovascular Risk Reports (Hughes, Kee and Salomaa).</gtr:impact><gtr:partnerContribution>The MORGAM Data Management Centre (MDC) is based at the National Institute of Health and Welfare. The MDC harmonizes the data from the various MORGAM participating centres and facilitates access to the database. The statistical analysis of the project is carried out here by MORGAM statisticians, datamanagers from this unit prepare datasets for analysis by other MORGAM collaborating Centres. Biomarker identification, selection and measurement is carried out at the Medical Clinic II laboratories at the Department of Cardiology in Mainz which moved to University Heart Centre, Hamburg, Germany in 2011.</gtr:partnerContribution><gtr:piContribution>The Principal Investigators have made a significant intellectual contribution to the project and faciliated access to the datasets.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>We evaluated the usefulness of 30 novel biomarkers to improve risk estimation for incident fatal and non-fatal cardiovascular disease events in the prospective community based samples from FINRISK and Belfast PRIME within the MORGAM project. The 30 novel biomarkers were chosen to represent distinct pathophysiological pathways, for example lipid metabolism, inflammation and myocardial necrosis. These were screened in the population based FINRISK97 cohort (7915 participants, 538 cases of incident CVD at 10 years follow up) and the Belfast PRIME cohort (2551 participants, 260 cases at 10 years of follow up). Of the 30 biomarkers the strongest associations with incident CVD events among FINRISK97 men and women and PRIME men were found between N-terminal pro-B-type natriuretic peptide (hazard ratio per increment standard deviation in FINRISK97 men cohort 1.23), C-reactive protein (1.23), B-type natriuretic peptide (1.19) and sensitive troponin I (1.18), but no single biomarker consistently improved risk estimation in these three cohorts. Statistical regression and lasso (penalized regression shrinkage) methods selected these three biomarkers; C-reactive protein, B-type natriuretic peptide and sensitive troponin I in combination with conventional risk factors for CVD including blood pressure, cholesterol level, body mass index and history of diabetes to establish a biomarker risk score in FINRISK97 cohort. Testing the biomarker score in the Belfast PRIME validation cohort consistently led to an improved risk estimation of cardiovascular disease.
We are investigating potential sources of funding to move into the next stage of product development i.e. refinement non-clinical and clinical. We are in the process of testing the assay parameters of the multiple biomarker score and assessing modality in additional prospective populations.</gtr:description><gtr:id>4ECE7C75-B688-4154-85B0-1F1AFC436407</gtr:id><gtr:impact>We have demonstrated that the biomarker risk score improves risk prediction of fatal and non-fatal cardiovascular events in two European cohorts. The biomarker risk score improves model discriminative accuracy (c-statistic P = 0.0022 in Belfast-PRIME) and also improves the Integrated Discrimination Index (P &amp;lt; 0.0001 in Belfast PRIME). The model improves classification of individuals across clinically defined strata of low (0-5%), intermediate (5-20%) and high (&amp;gt;20%) risk categories (P = 0.0007 in Belfast PRIME) compared to a traditional risk factor model. Indeed, 10 in every 100 patients would benefit from modified management due to this reclassification. The biomarker score has been internally and externally validated in two different European cohorts with high absolute risk of cardiovascular disease highlighting the potential generalizability of the score across several European regions.</gtr:impact><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Multiple biomarker risk score</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>ValidStats is an R package of statistical tools to facilitate model prediction and validation for analysing biomarkers. Validstats is freely available online through the R interface and contains various prediction model validation statistics (ROC, AUC, c-index, reclassification/NRI, decision curve, calibration) all adapted for censored survival data and allowing for weights. This package was written by Olli Saarela, primary MORGAM biomarker statistician based at the National Institute of Health and Welfare, Helsinki, Finland.</gtr:description><gtr:id>DD5233DD-49D9-4733-9D52-63C38459C65D</gtr:id><gtr:impact>These techniques were applied in Blankenberg et al. 2010 and are currently being used in other manuscripts using genetic and biomarker data being prepared by our group.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>ValidStats an R package of tools</gtr:title><gtr:type>Data analysis technique</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C999C89D-516A-474E-8FB9-7D19488C057B"><gtr:id>C999C89D-516A-474E-8FB9-7D19488C057B</gtr:id><gtr:title>New genetic loci link adipose and insulin biology to body fat distribution.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a085b336b6081bf206928f3cdcb91748"><gtr:id>a085b336b6081bf206928f3cdcb91748</gtr:id><gtr:otherNames>Shungin D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CCFA296B-1F8E-401C-863C-C6E09D3B9081"><gtr:id>CCFA296B-1F8E-401C-863C-C6E09D3B9081</gtr:id><gtr:title>The association between subgingival periodontal pathogens and systemic inflammation.</gtr:title><gtr:parentPublicationTitle>Journal of clinical periodontology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3806a9fda0c677582184de3fa80f3741"><gtr:id>3806a9fda0c677582184de3fa80f3741</gtr:id><gtr:otherNames>Winning L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0303-6979</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/414984CC-8CE4-4F41-94F5-22D7FB7A5B56"><gtr:id>414984CC-8CE4-4F41-94F5-22D7FB7A5B56</gtr:id><gtr:title>Smoking and All-cause Mortality in Older Adults: Results From the CHANCES Consortium.</gtr:title><gtr:parentPublicationTitle>American journal of preventive medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1d66130996dd2a4ca71be5dc0720e6c4"><gtr:id>1d66130996dd2a4ca71be5dc0720e6c4</gtr:id><gtr:otherNames>M?ezzinler A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0749-3797</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EAF79BDA-5AB6-4AE4-BAAF-E52A878F2435"><gtr:id>EAF79BDA-5AB6-4AE4-BAAF-E52A878F2435</gtr:id><gtr:title>Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium.</gtr:title><gtr:parentPublicationTitle>European heart journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/08190c7e4cd8984008f0602fcd74f1c3"><gtr:id>08190c7e4cd8984008f0602fcd74f1c3</gtr:id><gtr:otherNames>Blankenberg S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0195-668X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E43B558E-96F8-44F5-BF26-76B4237A2A87"><gtr:id>E43B558E-96F8-44F5-BF26-76B4237A2A87</gtr:id><gtr:title>Effect of major lifestyle risk factors, independent and jointly, on life expectancy with and without cardiovascular disease: results from the Consortium on Health and Ageing Network of Cohorts in Europe and the United States (CHANCES).</gtr:title><gtr:parentPublicationTitle>European journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/62dfd5ffdddd7b1494bab8c483685dac"><gtr:id>62dfd5ffdddd7b1494bab8c483685dac</gtr:id><gtr:otherNames>O'Doherty MG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0393-2990</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DF68A915-7BF2-47FF-B037-699F31052630"><gtr:id>DF68A915-7BF2-47FF-B037-699F31052630</gtr:id><gtr:title>Adiposity as a cause of cardiovascular disease: a Mendelian randomization study.</gtr:title><gtr:parentPublicationTitle>International journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8e4914927a342994c6f2decfa1f9d22a"><gtr:id>8e4914927a342994c6f2decfa1f9d22a</gtr:id><gtr:otherNames>H?gg S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0300-5771</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/463DDB86-7E83-4E68-AF83-36AE93F62105"><gtr:id>463DDB86-7E83-4E68-AF83-36AE93F62105</gtr:id><gtr:title>A multiple biomarker risk score for guiding clinical decisions using a decision curve approach.</gtr:title><gtr:parentPublicationTitle>European journal of preventive cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b23c77973e3db6748656de8b9a85444c"><gtr:id>b23c77973e3db6748656de8b9a85444c</gtr:id><gtr:otherNames>Hughes MF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2047-4873</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3E95CB2B-91F0-4E24-949F-0B8499BA9ED2"><gtr:id>3E95CB2B-91F0-4E24-949F-0B8499BA9ED2</gtr:id><gtr:title>Thirty-one novel biomarkers as predictors for clinically incident diabetes.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2ee8345b768b2df093ce971a278a24bc"><gtr:id>2ee8345b768b2df093ce971a278a24bc</gtr:id><gtr:otherNames>Salomaa V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/814EDBB7-3876-48E5-8458-AFB418A15141"><gtr:id>814EDBB7-3876-48E5-8458-AFB418A15141</gtr:id><gtr:title>Repeated measures of body mass index and C-reactive protein in relation to all-cause mortality and cardiovascular disease: results from the consortium on health and ageing network of cohorts in Europe and the United States (CHANCES).</gtr:title><gtr:parentPublicationTitle>European journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/62dfd5ffdddd7b1494bab8c483685dac"><gtr:id>62dfd5ffdddd7b1494bab8c483685dac</gtr:id><gtr:otherNames>O'Doherty MG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0393-2990</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0ACC912D-2229-407E-BAA8-5BED6A54AE14"><gtr:id>0ACC912D-2229-407E-BAA8-5BED6A54AE14</gtr:id><gtr:title>Vitamin D and mortality: meta-analysis of individual participant data from a large consortium of cohort studies from Europe and the United States.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5eb0c5936fc453a3d0e49898026b82d8"><gtr:id>5eb0c5936fc453a3d0e49898026b82d8</gtr:id><gtr:otherNames>Sch?ttker B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1F411A8E-F79F-420D-B848-1BDA8FDDC63A"><gtr:id>1F411A8E-F79F-420D-B848-1BDA8FDDC63A</gtr:id><gtr:title>The validity of heart failure diagnoses obtained from administrative registers.</gtr:title><gtr:parentPublicationTitle>European journal of preventive cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d55f0cda9868eb420d2c8f86f0d65022"><gtr:id>d55f0cda9868eb420d2c8f86f0d65022</gtr:id><gtr:otherNames>M?h?nen M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2047-4873</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7020A79D-2A6D-4F68-AD1E-7CB6DA0F3A95"><gtr:id>7020A79D-2A6D-4F68-AD1E-7CB6DA0F3A95</gtr:id><gtr:title>Associations between interleukin-1 (IL-1) gene variations or IL-1 receptor antagonist levels and the development of type 2 diabetes.</gtr:title><gtr:parentPublicationTitle>Journal of internal medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/046fb952b92e64d796de5f5cf41cdfda"><gtr:id>046fb952b92e64d796de5f5cf41cdfda</gtr:id><gtr:otherNames>Luotola K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0954-6820</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5CB8E7A9-C960-411B-95ED-E3D621D0827E"><gtr:id>5CB8E7A9-C960-411B-95ED-E3D621D0827E</gtr:id><gtr:title>The Predictive Value of Depressive Symptoms for All-Cause Mortality: Findings From the PRIME Belfast Study Examining the Role of Inflammation and Cardiovascular Risk Markers.</gtr:title><gtr:parentPublicationTitle>Psychosomatic medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b23c77973e3db6748656de8b9a85444c"><gtr:id>b23c77973e3db6748656de8b9a85444c</gtr:id><gtr:otherNames>Hughes MF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0033-3174</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/81961F04-805A-45EB-9937-C9C1C3EA9D6F"><gtr:id>81961F04-805A-45EB-9937-C9C1C3EA9D6F</gtr:id><gtr:title>High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort.</gtr:title><gtr:parentPublicationTitle>European heart journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a9c11a0373208a6a2759030a0d11302d"><gtr:id>a9c11a0373208a6a2759030a0d11302d</gtr:id><gtr:otherNames>Zeller T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0195-668X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EDC16A26-75C5-406F-8919-787A8E626302"><gtr:id>EDC16A26-75C5-406F-8919-787A8E626302</gtr:id><gtr:title>Genetic variation of the interleukin-1 family and nongenetic factors determining the interleukin-1 receptor antagonist phenotypes.</gtr:title><gtr:parentPublicationTitle>Metabolism: clinical and experimental</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/046fb952b92e64d796de5f5cf41cdfda"><gtr:id>046fb952b92e64d796de5f5cf41cdfda</gtr:id><gtr:otherNames>Luotola K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0026-0495</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7C4B61D8-F064-4C8A-B983-BBD5636882D5"><gtr:id>7C4B61D8-F064-4C8A-B983-BBD5636882D5</gtr:id><gtr:title>Mendelian randomization study of B-type natriuretic peptide and type 2 diabetes: evidence of causal association from population studies.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/005b980a45dcc103e05cdcdd21dce26c"><gtr:id>005b980a45dcc103e05cdcdd21dce26c</gtr:id><gtr:otherNames>Pfister R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/62912AEF-B78E-4D54-9D08-533CB695D369"><gtr:id>62912AEF-B78E-4D54-9D08-533CB695D369</gtr:id><gtr:title>All-Cause Mortality up to and After Coronary Heart Disease and Stroke Events in European Middle-Aged Men: The PRIME Study.</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4210559252eca2336f2b1d68894bee9a"><gtr:id>4210559252eca2336f2b1d68894bee9a</gtr:id><gtr:otherNames>Majed B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0039-2499</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2C05A506-9079-45C8-BEA9-F0591A4A074B"><gtr:id>2C05A506-9079-45C8-BEA9-F0591A4A074B</gtr:id><gtr:title>Defining the role of common variation in the genomic and biological architecture of adult human height.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d5c7dfb7949253c2a1b684d1952ae3ac"><gtr:id>d5c7dfb7949253c2a1b684d1952ae3ac</gtr:id><gtr:otherNames>Wood AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DE4E79B5-8D43-4525-B8F2-C44519DDA27D"><gtr:id>DE4E79B5-8D43-4525-B8F2-C44519DDA27D</gtr:id><gtr:title>Prime mover or fellow traveller: 25-hydroxy vitamin D's seasonal variation, cardiovascular disease and death in the Scottish Heart Health Extended Cohort (SHHEC).</gtr:title><gtr:parentPublicationTitle>International journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/da4ab92cd2562a2c219300506d5865fe"><gtr:id>da4ab92cd2562a2c219300506d5865fe</gtr:id><gtr:otherNames>Tunstall-Pedoe H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0300-5771</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B8F1B123-4D4F-429D-AC6D-60B8B90513A8"><gtr:id>B8F1B123-4D4F-429D-AC6D-60B8B90513A8</gtr:id><gtr:title>Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults: meta-analysis of individual participant data from prospective cohort studies of the CHANCES consortium.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e78167345ce6d1c4c28a48351567ea5b"><gtr:id>e78167345ce6d1c4c28a48351567ea5b</gtr:id><gtr:otherNames>Mons U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BBE641D3-7D3D-4A3D-AB06-D246DED5AD26"><gtr:id>BBE641D3-7D3D-4A3D-AB06-D246DED5AD26</gtr:id><gtr:title>Genetically determined height and coronary artery disease.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/27ab42a94bafa274f6486233c637c714"><gtr:id>27ab42a94bafa274f6486233c637c714</gtr:id><gtr:otherNames>Nelson CP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3D2F08BF-7BEB-4330-A3F0-202DDCA37B23"><gtr:id>3D2F08BF-7BEB-4330-A3F0-202DDCA37B23</gtr:id><gtr:title>Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/08190c7e4cd8984008f0602fcd74f1c3"><gtr:id>08190c7e4cd8984008f0602fcd74f1c3</gtr:id><gtr:otherNames>Blankenberg S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5F021395-097C-49B6-87C5-727B6E5FB7CC"><gtr:id>5F021395-097C-49B6-87C5-727B6E5FB7CC</gtr:id><gtr:title>WHO guidelines for a healthy diet and mortality from cardiovascular disease in European and American elderly: the CHANCES project.</gtr:title><gtr:parentPublicationTitle>The American journal of clinical nutrition</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f7a237eba9d45bc114011d8d57c9d65d"><gtr:id>f7a237eba9d45bc114011d8d57c9d65d</gtr:id><gtr:otherNames>Jankovic N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0002-9165</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601463</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>